Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.

zur Erlangung des akademischen Grades
Doctor medicinae (Dr. med.)

vorgelegt der Medizinischen Fakultät
Charité – Universitätsmedizin Berlin

von
Georg Marcus FRÖHLICH

aus Salzburg/Österreich

Datum der Promotion: 30. Mai 2015
Inhaltsverzeichnis

Abschnitt I
Abstract – English
Abstract – Deutsch

Abschnitt II
Eidesstattliche Versicherung

Abschnitt III
Auszug aus ISI Web of Knowledge

Abschnitt IV
Publikation

Abschnitt V
Lebenslauf

Abschnitt VI
Publikationsliste

Abschnitt VII
Danksagung
Abschnitt I
Abstracts
Abstract – English

**Objectives** This study was designed to delineate the role of implantable cardioverter defibrillator (ICD) therapy for the primary and secondary prevention of sudden cardiac death in patients listed for heart transplantation.

**Setting** Retrospective observational multicentre study.

**Patients** 1089 consecutive patients listed for heart transplantation in two tertiary heart transplant centres were enrolled. Of 550 patients (51%) on the transplant list with an ICD, 216 had received their ICD for the primary prevention of sudden cardiac death and 334 for secondary prevention. 539 patients did not receive an ICD.

**Intervention** Treatment with or without an ICD was left to the discretion of the heart failure specialist.

**Main outcome measure** All-cause mortality.

**Results** ICDs appear to be associated with a reduction in all-cause mortality in patients implanted with the device for primary and secondary prevention compared to those without an ICD despite a median time on the waiting list of only 8 months (estimated 1-year: 88±3% vs 77±3% vs 67±3%; p=0.0001). A Cox regressional hazard model (corrected for age, sex, underlying heart disease, atrial fibrillation, cardiac resynchronization therapy, New York Heart Association (NYHA) class, ejection fraction, co-medications and year of listing) suggested an independent beneficial effect of ICDs that was most pronounced in patients who had received an ICD for primary prevention (HR 0.4, 95% CI 0.19 to 0.85; p=0.016).

**Conclusions** ICD implantation appears to be associated with an immediate and sustained survival benefit for patients awaiting heart transplantation.
**Abstract – Deutsch**

**Studienziele** Diese Studie wurde dazu konzipiert den Vorteil eines implantierbaren Kardioverter Defibrillators (ICD) zur Primär- und Sekundärprävention des plötzlichen Herztodes bei Patienten welche zur Herztransplantation gelistet sind, zu eruieren.

**Studien-Setting** Retrospektive multicenter Studie

**Patienten** Es wurden 1089 konsekutive Patienten in die Studie eingeschlossen, welche zur Herztransplantation in zwei Herztransplantationszentren gelistet wurden. 550 Patienten (51%) auf der Warteliste erhielten einen ICD, 216 erhielten den ICD für die Primärprävention des plötzlichen Herztodes und 334 für Sekundärprävention. 539 Patienten erhielten keinen ICD. **Therapie** Behandlung mit oder ohne ICD.

**Primärer Endpunkt** Mortalität. **Resultate** Die ICD Implantation scheint mit einer Mortalitätsreduktion einherzugehen, sowohl bei Patienten mit Primärprävention also auch zur Sekundärprävention. Als Vergleichsgruppe wurden Patienten ohne ICD Implantation herangezogen. Dies ist umso bemerkenswerter, als die mediane Wartezeit bis zur Herztransplantation gerade 8 Monate betrug. Das geschätzte 1-Jahres Überleben war für die genannten Gruppen: 88±3% vs 77±3% vs 67±3%; p=0.0001. Eine multivariate Cox Regressionsanalyse (korrigiert für Alter, Geschlecht, zu Grunde liegende Herzerkrankung, Vorhofflimmern, kardiale Resynchronisationstherapie, New York Heart Association (NYHA) class, Ejektionsfraktion, Co-Medikation and Jahr der Listung) suggeriert einen unabhängigen Überlebensvorteil für die ICD Implantation, welcher bei Patienten mit Primärprävention besonders ausgeprägt war (HR 0.4, 95% CI 0.19 to 0.85; p=0.016).

**Conclusion** Bei Patienten auf der Herztransplantationswarteliste war die Implantation eines ICDs mit einem sofortigen und anhaltenden Überlebensvorteil verbunden.
Abschnitt II

Eidesstattliche Versicherung
Eidesstattliche Versicherung


Die Bedeutung dieser eidesstattlichen Versicherung und die strafrechtlichen Folgen einer unwahren eidesstatlichen Versicherung (§156,161 des Strafgesetzbuches) sind mir bekannt und bewusst."

Datum 07.10.2014

Unterschrift

Ausführliche Anteilserklärung an der erfolgten Publikation

Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.


Mein Beitrag zur Publikation:
1. Idee
2. Koordination der Studienzentren in Zürich und im Herzzentrum Berlin
3. Datenbankerstellung mit unsererm Statistik der Universität Zürich (Prof. Seifert)
4. Erstellung des Manuskripts
5. Publikation
Unterschrift, Datum und Stempel des betreuenden Hochschullehrers/der betreuenden Hochschullehrerin

________________________

Unterschrift des Doktoranden/der Doktorandin

________________________
Abschnitt III
Auszug aus Isl Web of Knowledge
### Journal Summary List

**Sorted by:** Impact Factor

<table>
<thead>
<tr>
<th>Mark</th>
<th>Rank</th>
<th>Abbreviated Journal Title (linked to journal information)</th>
<th>ISSN</th>
<th>JCR Data</th>
<th>Eigenfactor Metrics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total Cites</td>
<td>Impact Factor</td>
</tr>
<tr>
<td>☐</td>
<td>1</td>
<td>JAM COLL CARDIOL</td>
<td>0735-1097</td>
<td>79235</td>
<td>15.343</td>
</tr>
<tr>
<td>☐</td>
<td>2</td>
<td>CIRCULATION</td>
<td>0009-7322</td>
<td>158661</td>
<td>14.948</td>
</tr>
<tr>
<td>☐</td>
<td>3</td>
<td>EUR HEART J</td>
<td>0195-668X</td>
<td>36613</td>
<td>14.723</td>
</tr>
<tr>
<td>☐</td>
<td>4</td>
<td>CIRC RES</td>
<td>0009-7330</td>
<td>47185</td>
<td>11.089</td>
</tr>
<tr>
<td>☐</td>
<td>5</td>
<td>NAT REV CARDIOL</td>
<td>1759-5002</td>
<td>2196</td>
<td>10.154</td>
</tr>
<tr>
<td>☐</td>
<td>6</td>
<td>JACC-CARDIOVASC INTE</td>
<td>1936-8798</td>
<td>4558</td>
<td>7.440</td>
</tr>
<tr>
<td>☐</td>
<td>7</td>
<td>JACC-CARDIOVASC IMAG</td>
<td>1936-878X</td>
<td>3744</td>
<td>6.986</td>
</tr>
<tr>
<td>☐</td>
<td>8</td>
<td>CIRC-CARDIOVASC INTE</td>
<td>1941-7640</td>
<td>2311</td>
<td>6.982</td>
</tr>
<tr>
<td>☐</td>
<td>9</td>
<td>CIRC-CARDIOVASC IMAG</td>
<td>1941-9651</td>
<td>2341</td>
<td>6.752</td>
</tr>
<tr>
<td>☐</td>
<td>10</td>
<td>EUR J HEART FAIL</td>
<td>1388-9842</td>
<td>6854</td>
<td>6.577</td>
</tr>
<tr>
<td>☐</td>
<td>11</td>
<td>INT J CARDIOL</td>
<td>0167-5273</td>
<td>15179</td>
<td>6.175</td>
</tr>
<tr>
<td>☐</td>
<td>12</td>
<td>HEART</td>
<td>1355-6037</td>
<td>15342</td>
<td>6.023</td>
</tr>
<tr>
<td>☐</td>
<td>13</td>
<td>BASIC RES CARDIOL</td>
<td>0300-9428</td>
<td>3697</td>
<td>5.955</td>
</tr>
<tr>
<td>☐</td>
<td>14</td>
<td>CIRC-HEART FAIL</td>
<td>1941-3289</td>
<td>2602</td>
<td>5.945</td>
</tr>
<tr>
<td>☐</td>
<td>15</td>
<td>CARDIOVASC RES</td>
<td>0008-6363</td>
<td>21631</td>
<td>5.808</td>
</tr>
<tr>
<td>☐</td>
<td>16</td>
<td>EUR HEART J SUPPL</td>
<td>1520-765X</td>
<td>985</td>
<td>5.640</td>
</tr>
<tr>
<td>☐</td>
<td>17</td>
<td>J HEART LUNG TRANSPL</td>
<td>1053-2498</td>
<td>8078</td>
<td>5.611</td>
</tr>
<tr>
<td>☐</td>
<td>18</td>
<td>CIRC-ARHYTHMIA ELEC</td>
<td>1941-3149</td>
<td>3017</td>
<td>5.417</td>
</tr>
<tr>
<td>☐</td>
<td>19</td>
<td>CIRC-CARDIOVASC GENE</td>
<td>1942-3268</td>
<td>1959</td>
<td>5.337</td>
</tr>
<tr>
<td>☐</td>
<td>20</td>
<td>1 MOL CELL CARDIOL</td>
<td>0022-2828</td>
<td>12451</td>
<td>5.218</td>
</tr>
</tbody>
</table>
Abschnitt IV
Publikation
Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation

Georg M Fröhlich,1 Johannes Holzmeister,1 Michael Hübler,2 Samira Hübler,2 Mathias Wolfreim,1 Frank Enseleit,1 Burkhardt Seifter,2 David Hürlimann,1 Hans B Lehmkuhl,2 Georg Noll,1 Jan Steffel,1 Volkmar Falk,4 Thomas F Lüscher,1 Roland Hetzer,2 Frank Ruschitzka1

ABSTRACT
Objectives This study was designed to delineate the role of implantable cardioverter defibrillator (ICD) therapy for the primary and secondary prevention of sudden cardiac death in patients listed for heart transplantation.

Setting Retrospective observational multicenter study.

Patients 1089 consecutive patients listed for heart transplantation in two tertiary heart transplant centres were enrolled. Of 550 patients (51%) on the transplant list with an ICD, 216 had received their ICD for the primary prevention of sudden cardiac death and 334 for secondary prevention. 539 patients did not receive an ICD.

Intervention Treatment with or without an ICD was left to the discretion of the heart failure specialist.

Main outcome measure All-cause mortality.

Results ICDs appear to be associated with a reduction in all-cause mortality in patients implanted with the device for primary and secondary prevention compared to those without an ICD despite a median time on the waiting list of only 8 months (estimated 1-year: 88.3% vs 77.3% vs 67.3%; p=0.0001). A Cox regression model (corrected for age, sex, underlying heart disease, atrial fibrillation, cardiac resynchronisation therapy, New York Heart Association (NYHA) class, ejection fraction, co-medication and year of listing) suggested an independent beneficial effect of ICDs that was most pronounced in patients who had received an ICD for primary prevention (HR 0.4, 95% CI 0.19 to 0.85, p=0.016).

Conclusions ICD implantation appears to be associated with an immediate and sustained survival benefit for patients awaiting heart transplantation.

INTRODUCTION
In December 2010, a total of 3225 patients in the USA were listed for heart transplantation, while 232 had died on the waiting list the year before. To improve the survival rates of patients with end-stage heart failure, treatment with implantable cardioverter defibrillators (ICDs) has been proposed to prevent sudden cardiac death.1 2 Large scale randomised clinical trials have confirmed a significant survival benefit of ICD implantation in patients with mild to moderate chronic heart failure, but only a few patients in New York Heart Association (NYHA) class IV heart failure were included in these landmark trials.3 6 Whether candidates for heart transplantation should receive an ICD to reduce the risk of sudden cardiac death while awaiting cardiac transplantation is matter of ongoing debate.7 8 Indeed, only a few relatively small studies have addressed the role of ICD implantation in patients on the waiting list for heart transplantation, with conflicting results.9-13 While these studies suggested the implementation of an ICD was beneficial for secondary prevention in patients who had survived a life-threatening ventricular arrhythmia, its efficacy has not yet been sufficiently investigated for primary prevention. The present study was therefore designed to evaluate the role of ICD therapy for the prevention of sudden cardiac death in heart failure patients listed for heart transplantation.

METHODS
Patient recruitment and inclusion criteria
Patients in two tertiary heart transplant centres (the Department of Cardiology, University Hospital Zurich and the German Heart Centre Berlin) from 1996 (the year the MADIT I study was published) to September 2010 were retrospectively included in the study.14 Decision criteria for transplant listing followed ISHLT standards and were similar in both centres.15-17 and included a history of NYHA class IV heart failure and a VO2 max <14 mL/kg/min.

All patients aged 16 years or older listed for a heart transplant were eligible for inclusion. Patients were excluded if no data on prior ventricular arrhythmia (defined as sustained ventricular tachycardia or ventricular fibrillation) were available at the time of listing, or if serial follow-up data on ICD function and shock delivery were lacking. Patients who received a cardiac assist device before listing were also excluded. At the time of listing, current medication, NYHA functional class, ejection fraction, electrocardiography, data on cardiovascular risk factors and underlying heart disease were documented.

Patients were followed until heart transplantation for a maximum of 3 years. The date and cause of death, date of heart transplantation or date of assist device implantation was recorded. If cardiac death occurred, cases were sub-classified as 'sudden cardiac death' (defined as death within 1 h after the
onset of acute symptoms or unwatched, unexpected death in a patient known to have been stable within the previous 24 h, ‘non-sudden cardiac death’ or death due to ‘low cardiac output’ (defined as death due to progressive congestive heart failure or with preceding symptoms lasting >1 h). Patients in whom classification was not possible were termed ‘not classified’.

ICD implantation and programming

Patients in the primary prevention group received the ICD because of sustained ventricular arrhythmia, ventricular fibrillation or survival of sudden cardiac death. Patients in the primary prevention group were treated by heart failure specialists who decided if ICD implantation was indicated on an individual basis. This clinical practice reflects the inherent uncertainty regarding the eligibility of patients on the heart transplant waiting list to receive an ICD in the absence of trial outcome data.

ICD devices made by Medtronic, Guidant/Boston Scientific, Biotronik and St. Jude Medical were used. More than 90% of patients had one or two ventricular tachycardia zones programmed for antitachycardia pacing. The ventricular fibrillation zone was programmed at a cut-off heart rate of >200/min. Right ventricular pacing >50% of time occurred in less than 10% of patients (except in patients undergoing cardiac resynchronisation therapy (CRT)).

Study groups and study endpoints

The indication for ICD implantation was re-evaluated in each patient by two experienced investigators (GMF and MW) with consequent allocation to either the ‘primary prevention’ or the ‘secondary prevention’ group. A total of 478 patients (87%) had received their ICD before listing (with 1088 patient-years until listing). This guaranteed permanent rhythm surveillance and served as a basis to accurately assign the patients either to the primary or secondary prevention group.

The main criterion to classify implantation as secondary prevention was documentation of a previous severe ventricular arrhythmia (i.e., sustained ventricular arrhythmia or ventricular fibrillation). Patients who had originally received the ICD for primary prevention, who had had shock delivery prior to transplant listing, were also allocated to the secondary prevention group. Patients who received the ICD after being listed for transplantation, were all allocated to the one of the ICD groups. In case of documented arrhythmic events before ICD implantation, these patients were assigned to the secondary prevention group. Investigators adjudicating outcome data were blinded for study group allocation to primary versus secondary prevention. Patients without an ICD were allocated to the control group.

The primary outcome measure of our study was death from any cause. Secondary endpoints were death from any cause, need for the implantation of a ventricular assist device, or appropriate shock delivery while on the transplant list. Safety issues concerning the ICD therapy (appropriate versus inappropriate shock delivery; need for reoperation while on the transplant list) were also recorded. Further, the subgroup of patients with cardiac resynchronisation therapy plus defibrillator (CRT-D) was analysed for overall survival versus those with ICDs alone and those without any devices.

RESULTS

Patient population and characteristics

Between 1996 and September 2010, a total of 1489 patients were listed for heart transplantation at the two centres. Of these, 221 patients were excluded due to implantation of an assist device before listing, and 30 due to incomplete source documentation. In addition, 149 patients were less than 16 years of age and were excluded. As a result, 1089 patients (944 patients from the German Heart Center Berlin and 145 patients from University Hospital Zurich) were included in the analysis (figure 1). Heart failure therapy, follow-up procedures and the selection of patients for heart transplantation were comparable in the two centres. Baseline characteristics are summarised in table 1. Median ejection fraction at the time of listing was 20% (IQR 15–25%) and most patients were in NYHA functional class II (n=713, 66%). The main cause of heart failure was dilated cardiomyopathy (n=602, 55%), followed by ischaemic cardiomyopathy (n=352, 32%).

Of the 1089 patients included in the study, 583 (54%) underwent transplantation within 3 years of being listed for heart transplantation after having been on the transplant list for a median (IQR) time of 281 (80–664) days. A total of 290 patients (27%) listed for transplantation died during the observation period of 3 years after listing for cardiac transplantation, which is in line with recent US and European data. A total of 228 patients (21%) received an assist device (table 2).

Of the 550 patients with an ICD, 478 (87%) had received an ICD before listing for transplantation and 72 (13%) after being listed (median IQR) 108 (14–320) days after listing.

Effect of ICD on all-cause mortality

A total of 550 patients (51%) on the transplant list received an ICD, which was implanted in 216 (20%) and 334 patients (31%) for primary and secondary prevention, respectively. As regards all-cause mortality, ICD treatment may have a beneficial...
Figure 1  Flow chart showing which patients were excluded from the study.

1489 patients listed for heart transplantation in both centres

221 patients excluded due to implantation of an assist device before listing for transplant

1268 patients

149 patients were <16 years old

1119 patients

30 patients had incomplete documentation

1089 patients finally included

Table 1  Baseline characteristics at the time of listing for heart transplantation

<table>
<thead>
<tr>
<th></th>
<th>No ICD (n=539)</th>
<th>Primary prevention ICD (n=216)</th>
<th>Secondary prevention ICD (n=334)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (QQR)</td>
<td>52 (43–59)</td>
<td>53 (43–59)</td>
<td>55 (42–59)</td>
<td>0.02</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>432 (80)</td>
<td>189 (88)</td>
<td>268 (86)</td>
<td>0.01</td>
</tr>
<tr>
<td>Body mass index, kg/m² (QQR)</td>
<td>25 (22–28)</td>
<td>25 (23–29)</td>
<td>25 (22–28)</td>
<td>0.05</td>
</tr>
<tr>
<td>Rhythm, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Sinus rhythm</td>
<td>330 (66)</td>
<td>120 (57)</td>
<td>191 (60)</td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>100 (20)</td>
<td>42 (20)</td>
<td>60 (19)</td>
<td></td>
</tr>
<tr>
<td>Pacemaker</td>
<td>64 (13)</td>
<td>47 (23)</td>
<td>67 (21)</td>
<td></td>
</tr>
<tr>
<td>Left bundle branch block, n (%)</td>
<td>215 (44)</td>
<td>97 (46)</td>
<td>159 (40)</td>
<td>0.39</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>20 (15–25)</td>
<td>20 (15–25)</td>
<td>20 (15–25)</td>
<td>0.24</td>
</tr>
<tr>
<td>CRT-D, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>NYHA functional class, n (%)</td>
<td>15 (3)</td>
<td>11 (5)</td>
<td>20 (6)</td>
<td>0.27</td>
</tr>
<tr>
<td>II</td>
<td>343 (68)</td>
<td>148 (70)</td>
<td>222 (67)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>145 (29)</td>
<td>52 (25)</td>
<td>90 (27)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular risk factors, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>164 (36)</td>
<td>86 (47)</td>
<td>135 (49)</td>
<td>0.001</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>169 (37)</td>
<td>90 (50)</td>
<td>138 (50)</td>
<td>0.0005</td>
</tr>
<tr>
<td>Diabetes</td>
<td>95 (21)</td>
<td>50 (23)</td>
<td>66 (24)</td>
<td>0.18</td>
</tr>
<tr>
<td>Smoking</td>
<td>96 (21)</td>
<td>51 (22)</td>
<td>69 (23)</td>
<td>0.13</td>
</tr>
<tr>
<td>Cause of cardiomyopathy, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dilated cardiomyopathy</td>
<td>282 (52)</td>
<td>119 (55)</td>
<td>201 (60)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ischaemic cardiomyopathy</td>
<td>167 (31)</td>
<td>80 (37)</td>
<td>105 (31)</td>
<td></td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>25 (5)</td>
<td>10 (5)</td>
<td>11 (3)</td>
<td></td>
</tr>
<tr>
<td>Congenital cardiomyopathy</td>
<td>22 (4)</td>
<td>2 (1)</td>
<td>4 (1)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>41 (8)</td>
<td>3 (1)</td>
<td>12 (4)</td>
<td></td>
</tr>
<tr>
<td>Medication, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Blocker</td>
<td>271 (57)</td>
<td>169 (80)</td>
<td>240 (74)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ACE inhibitors/ATI blocker</td>
<td>417 (87)</td>
<td>191 (90)</td>
<td>276 (85)</td>
<td>0.28</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>213 (44)</td>
<td>149 (70)</td>
<td>191 (59)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Digoxine</td>
<td>360 (75)</td>
<td>140 (66)</td>
<td>229 (71)</td>
<td>0.05</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>192 (32)</td>
<td>52 (25)</td>
<td>125 (36)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diuretics</td>
<td>425 (90)</td>
<td>196 (93)</td>
<td>292 (86)</td>
<td>0.66</td>
</tr>
</tbody>
</table>

Number of patients (%) and median (IQR) are shown for categorical and continuous data, respectively.
CMT-D, cardiac resynchronisation therapy plus defibrillator; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association.
Table 2  Three-year follow-up and adverse events

<table>
<thead>
<tr>
<th></th>
<th>No ICD (n=539)</th>
<th>Primary prevention (n=216)</th>
<th>Secondary prevention (n=334)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart transplantation, n (%)</td>
<td>285 (53)</td>
<td>119 (55)</td>
<td>178 (53)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Waiting time on list, days (IQR)</td>
<td>194 (56–469)</td>
<td>420 (144–883)</td>
<td>331 (103–708)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Death on list, n (%)</td>
<td>162 (30)</td>
<td>39 (18)</td>
<td>89 (27)</td>
<td></td>
</tr>
<tr>
<td>Cardiac death</td>
<td>113 (70)</td>
<td>22 (56)</td>
<td>42 (47)</td>
<td></td>
</tr>
<tr>
<td>Cerebral event leading to death</td>
<td>10 (6)</td>
<td>3 (8)</td>
<td>9 (10)</td>
<td></td>
</tr>
<tr>
<td>Fatal bleeding</td>
<td>0</td>
<td>0</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Multiorgan failure</td>
<td>12 (8)</td>
<td>5 (13)</td>
<td>10 (11)</td>
<td></td>
</tr>
<tr>
<td>Malignancy</td>
<td>2 (1)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Septic shock</td>
<td>17 (11)</td>
<td>8 (21)</td>
<td>23 (26)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>7 (4)</td>
<td>1 (3)</td>
<td>2 (2)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (1)</td>
<td>0</td>
<td>2 (2)</td>
<td></td>
</tr>
<tr>
<td>Ventricular assist device, n (%)</td>
<td>86 (16)</td>
<td>48 (22)</td>
<td>94 (28)</td>
<td></td>
</tr>
<tr>
<td>Patients with appropriate shock delivery on list, n (%)</td>
<td>22 (10)</td>
<td>22 (10)</td>
<td>58 (18)</td>
<td></td>
</tr>
<tr>
<td>Appropriate shock delivery (1-year event free survival, %)</td>
<td>89±3</td>
<td>89±3</td>
<td>89±3</td>
<td>0.003</td>
</tr>
<tr>
<td>Appropriate shocks for VT, n (%)</td>
<td>40 (54)</td>
<td>40 (54)</td>
<td>134 (53)</td>
<td></td>
</tr>
<tr>
<td>Appropriate shocks for VF, n (%)</td>
<td>23 (20)</td>
<td>23 (20)</td>
<td>79 (31)</td>
<td></td>
</tr>
<tr>
<td>Cardiac death (1-year cardiac survival, %)</td>
<td>76±2</td>
<td>94±2</td>
<td>88±2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sudden cardiac death</td>
<td>76±3</td>
<td>99±1</td>
<td>96±2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Low cardiac output</td>
<td>94±1</td>
<td>95±2</td>
<td>91±2</td>
<td>0.11</td>
</tr>
<tr>
<td>Unclassified</td>
<td>94±1</td>
<td>99±1</td>
<td>98±1</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Number of patients (%) and mean (IQR) are shown for categorical and continuous data, respectively. ICD, implantable cardioverter defibrillator; VT, ventricular tachycardia.

Effect in the primary as well as in the secondary prevention group when compared to patients without an ICD (control group) (p=0.0001; figure 2A). The survival benefit was more pronounced in the primary prevention (1-year estimator: 88±3% vs 67±3%; p<0.0001) than the control group, as compared to patients who received an ICD for secondary prevention versus the control group (77±3% vs 67±3%; p=0.01). This survival benefit remained after correction for several covariates in a Cox regression model which included 969 complete cases (table 3; proportional hazard assumption: p=0.38). No interactions of ICD treatment with other covariates on the outcome measure could be detected. A stratified propensity score analysis (including 586 complete cases from the primary prevention and control groups) suggested a similar survival benefit for the primary prevention group as for the control group (p=0.017).

The p value of the Hosmer–Lemeshow test was 0.54, and the c value was 0.80. Importantly, the number needed to treat over a 6-month period at risk was eight, indicating that eight patients would need to be implanted with an ICD for a primary prophylactic indication over 6 months to save one life.

Similarly, in patients who received an ICD after listing (n=72), a significant survival benefit was observed for the primary as well as for the secondary prevention group when compared to those without an ICD (1-year event free survival: 86±6% vs 78±9% vs 67±3%; p=0.009) (figure 3A).

Figure 2  Effect of ICD treatment on all-cause mortality and/or need for an assist device. Kaplan–Meier curves for freedom from all-cause mortality (A) and death from any cause or need for implantation of an assist device (B) in patients without ICDs, primary prevention ICD recipients, and secondary prevention ICD recipients. ICD, implantable cardioverter defibrillator; prev., prevention.

**Effect of ICD treatment on mortality and need for an assist device**
Overall, 203 patients (38%) in the control, 64 (30%) in the primary prevention and 132 (40%) in the secondary prevention group died or needed an assist device (figure 2B). On Kaplan-Meier analysis, event free survival was documented in more patients in the primary prevention (1-year estimator: 77±3%) as compared to the secondary prevention (61±3%) and control cohorts (58±3%; p=0.03). This benefit became evident from the first day of study inclusion (figure 2). In contrast, no significant difference was observed between the secondary prevention and the control group.

In the group of patients who received the ICD after listing, event free survival was significantly prolonged in both groups who received the ICD for primary and secondary prevention as compared to patients without an ICD (1-year estimator: 80±7% vs 73±9 vs 58±3%; p=0.002; figure 3B).

**CAUSES OF CARDIAC DEATH**

Overall, 113 (70%), 22 (56%) and 42 (47%) patients died of a cardiac cause in the control, primary prevention and secondary prevention groups, respectively (table 2). Patients in the control group were more likely to die from sudden cardiac death (1-year event free survival: 86±2%) as compared to patients without an ICD (99±1%; p<0.0001). In contrast, no differences in death from low cardiac output were observed between the control (94±1%), primary prevention (95±2%) and secondary prevention groups (91±2%; 1-year event free survival estimator: p=0.11).

**SAFETY OF ICD THERAPY**

Tables 2 and 4 summarise the total number of patients with shock deliveries as well as the number of shock deliveries. Appropriate (ventricular tachycardia or ventricular fibrillation) and inappropriate shock deliveries (atrial fibrillation, electrode or device defects) while patients were listed for heart transplantation were identified. The striking difference in the number of inappropriate shocks between the primary and secondary prevention groups is due to one patient with an electrical storm who received 36 shocks. All re-operations for lead dislocation, lead fracture or malfunction of the ICD device occurring during the listing period are presented in table 4.

---

**Table 3** Cox regression analysis for the primary endpoint of all-cause mortality

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary prevention versus no ICD</td>
<td>0.40 (0.19 to 0.85)</td>
<td>0.016</td>
</tr>
<tr>
<td>Secondary prevention versus no ICD</td>
<td>0.48 (0.26 to 0.89)</td>
<td>0.019</td>
</tr>
<tr>
<td>CRT-D versus ICD</td>
<td>0.76 (0.45 to 1.29)</td>
<td>0.31</td>
</tr>
<tr>
<td>Age (&gt;60 years vs &lt;60 years)</td>
<td>1.21 (0.87 to 1.68)</td>
<td>0.27</td>
</tr>
<tr>
<td>Male</td>
<td>0.63 (0.43 to 0.92)</td>
<td>0.02</td>
</tr>
<tr>
<td>Ischaemic cardiomyopathy</td>
<td>0.76 (0.52 to 1.1)</td>
<td>0.15</td>
</tr>
<tr>
<td>Atrial fibrillation versus sinus rhythm</td>
<td>1.51 (0.99 to 2.29)</td>
<td>0.05</td>
</tr>
<tr>
<td>ß-blocker</td>
<td>0.80 (0.59 to 1.09)</td>
<td>0.17</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>0.96 (0.72 to 1.27)</td>
<td>0.78</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>1.15 (0.75 to 1.76)</td>
<td>0.52</td>
</tr>
<tr>
<td>NYHA class III versus NYHA II</td>
<td>1.79 (0.78 to 4.1)</td>
<td>0.17</td>
</tr>
<tr>
<td>NYHA class IV versus NYHA II</td>
<td>2.28 (0.98 to 5.34)</td>
<td>0.06</td>
</tr>
<tr>
<td>EF (&gt;20% vs &lt;20%)</td>
<td>0.83 (0.62 to 1.09)</td>
<td>0.18</td>
</tr>
<tr>
<td>Year of listing for transplantation (per year)</td>
<td>1.02 (0.88 to 1.06)</td>
<td>0.37</td>
</tr>
</tbody>
</table>

- HRs and 95% CIs are presented.
- CRT-D, cardiac resynchronization therapy plus defibrillator; EF, ejection fraction; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association.

---

**Table 4** Safety issues in patients after implantable cardioverter defibrillator (ICD) implantation while listed for heart transplantation

<table>
<thead>
<tr>
<th></th>
<th>Primary prevention (n=218)</th>
<th>Secondary prevention (n=334)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with inappropriate shocks, n (%)</td>
<td>10 (5)</td>
<td>17 (5)</td>
</tr>
<tr>
<td>(Inappropriate) shocks for atrial fibrillation, n (%)</td>
<td>7 (3)</td>
<td>11 (4)</td>
</tr>
<tr>
<td>Inappropriate shocks for device/electrode malfunction, n (%)</td>
<td>47 (40)</td>
<td>21 (8)</td>
</tr>
<tr>
<td>Patients with need for ICD surgery while on the transplant list, n (%)</td>
<td>6 (3)</td>
<td>18 (5)</td>
</tr>
</tbody>
</table>

---

**Figure 3**

- **A**: Effect of ICD in patients implanted while on the transplant waiting list. The effect of ICD treatment on freedom from all-cause mortality (A) and death from any cause or need for implantation of an assist device (B) in patients implanted on the transplant waiting list. ICD, implantable cardioverter defibrillator; prev., prevention.
Impact of CRT on survival

Of the 550 patients with an ICD, 104 (19%) had a biventricular CRT-D system (52 patients (24%) in the primary prevention group and 52 patients (16%) in the secondary prevention group). Patients without an ICD were more likely to die on the list compared to the CRT-D and ICD groups (1-year estimator: 67±3% vs 83±4% vs 81±2%; p = 0.0006; figure 4). Although the HR was lowered by 24% in the CRT-D group, this was not statistically significant when compared to patients with an ICD alone (table 3). However, the investigated number of cases with CRT-D might have been too low to detect a significant survival benefit.

DISCUSSION

This observational study suggests that ICD implantation results in a reduction in sudden cardiac death, leading to an immediate and sustained survival benefit for candidates listed for heart transplantation despite a median time on the waiting list of only 8 months. Patients who received the ICD for primary prevention before listing as well as patients receiving an ICD (primary and secondary prevention) after being listed for transplantation appear to derive the greatest benefit.

Although ICD trials have demonstrated a benefit of ICD implantation for primary prevention in high-risk patients with ischaemic and non-ischaemic cardiomyopathy, the subgroup of highly symptomatic patients in NYHA class IV with a particularly poor prognosis was mostly excluded from these earlier trials. Indeed, the SCVD-HT trial study included only patients with stable NYHA class II or III heart failure, and excluded those with NYHA class IV heart failure and/or candidates for heart transplantation.24 In contrast, MADIT-2 inclusion criteria required only a low ejection fraction and did not include clinical symptoms of heart failure. In view of the paucity of end-stage heart failure patients in ICD trials, recommendations on prophylactic ICD implantation in patients with end-stage heart failure are somewhat conflicting. The ACC/AHA guidelines currently assign a class IIa (level of evidence C) recommendation for ICD implantation in non-hospitalised patients awaiting heart transplantation. In contrast, ICD implantation is not recommended for patients without a reasonable expectation of survival with an acceptable functional status for at least 1 year (class III, level of evidence C). As a result, only 5/7% of patients who were eligible for ICD implantation, already had an ICD at the first consultation in a tertiary cardiac care centre.22

As randomised clinical trials addressing this issue are unavailable and it might be difficult to conduct them due to ethical concerns, only a few retrospective studies, mostly including low numbers of patients, are currently used to guide clinical practice. The largest study so far, which enrolled 854 patients listed for transplantation, demonstrated a survival benefit for the 102 patients (12%) with an ICD awaiting heart transplantation; however, no information was provided on whether the decision to implant an ICD was based on a primary or secondary prevention indication. Importantly, the latter study was published in 2001, several years before large scale randomised trials demonstrated the benefit of ICD implantation for the primary prevention of sudden cardiac death, which may explain the low overall number of implanted ICDS.4,21

A survival benefit comparable to that in our report was observed in a recent study of 310 patients listed for heart transplantation, of whom 59 (19%) received an ICD for secondary prevention;10,11 however, no patients with primary preventive ICD implantation were included in this study. In another cohort of 194 patients on the transplant list and in which only 35 patients underwent ICD implantation, 40 (25.2%) patients died in the control group and three (8.6%) in the ICD groups.10,11

In contrast, our study evaluated a total of 1089 patients, of whom 359 (51%) received an ICD during the period 1996–2010, thus reflecting the implementation of recent landmark trial results in addition to state-of-the-art heart failure treatment algorithms in a large cohort of patients. Importantly, while most of the previous studies examined the effect of ICD treatment for secondary prevention, we here for the first time observed a pronounced survival benefit of primary and secondary preventive ICD therapy in patients listed for heart transplantation. While ICD implantation appears to be associated with a reduction in all-cause mortality in patients who received the device for primary or secondary prevention, when the combined outcome measure consisting of death or need for assist device implantation was analysed, no advantage could be observed in patients who received an ICD for secondary prevention. This result is due to the increased propensity of low cardiac output failure in these patients and a consequent increased need for cardiac assist device implantation.

Moreover, patients who had received ICD implantation after being listed for transplantation derived a significant benefit as regards both all-cause mortality and the combined outcome measure of all-cause mortality or need for assist device implantation as compared to those without an ICD. Taken together, our data hence imply that patients accepted for listing and those already listed for cardiac transplantation will derive a substantial benefit from ICD implantation independent of a previously documented life-threatening arrhythmic event.

Indications for ICD implantation need to be critically evaluated for their efficacy, especially if the time at risk of sudden cardiac death is relatively short as in patients awaiting heart transplantation. Indeed, with a number needed to treat of eight patients to save one life over 6 months, the present study provides strong evidence that this treatment is highly effective. This apparent benefit, however, has to be carefully weighed against the safety concerns potentially associated with ICD therapy, particularly as the retrospective cohort study of cases...
submitted to the US National Cardiovascular Data Registry. ICD Registry demonstrated that adverse events were significantly higher in patients who received a currently non-evidence-based device.7

Importantly, the ICD related complication rate in the present study was comparable to that of large randomised ICD trials and observational studies.8 23 Therefore, any decision to implant an ICD in this patient cohort at particularly increased risk needs to be individualised and the clinical equipoise of ICD therapy considered.7

Of note, while patients with ICD only and those with CRT-D showed a significant survival benefit compared to the control group, no statistically significant difference between the ICD group and the CRT-D group could be detected, indicating that CRT did not provide an additional survival benefit in this patient population. Similarly, a smaller prospective study including 80 patients with NYHA class IV heart failure failed to detect any survival benefit between the patients with ICDs only versus those with CRT-D,24 suggesting a 'point of no return' in ventricular remodelling after which the otherwise highly effective treatment with CRT may no longer improve ventricular structure and function. These findings have to be interpreted with caution, as the number of patients who received CRT-D might have been too low to detect a survival benefit for resynchronisation therapy. Further, prospective trials are now needed to confirm or refute the findings of this observational study.

**Limitations**

The three study groups differ slightly with respect to several baseline characteristics, including underlying heart disease and co-medication, reflecting the inclusion of patients in a real world setting. Indeed, compared to large scale prospective randomised clinical trials that included patients with NYHA class III or IV heart failure, such as the COMPANION trial, the proportion of patients receiving β-blockers (67% vs 62%), ACE/AT1 inhibitors (89% vs 82%) or spironolactone (54% vs 31%) in our study was very similar.8 In line with our findings, it has been demonstrated previously that the ICD benefit is independent of concomitant β-blocker or amiodarone therapy.9 10

To overcome the problem of different proportions of patients receiving β-blocker and spironolactone co-medication and the relatively long observational period, we also performed a survival analysis including only patients listed for transplantation after 2002 (ie, when MADIT II was published; n=439). In this patient population, β-blocker and spironolactone treatment was balanced between the study groups, but the survival benefit for the ICD treatment groups was comparable to the entire study population (data not shown).

Moreover, a large proportion of our patients enrolled in the control group (n=386, 71%) were listed for transplantation before 2002, whereas the 62% in the ICD group (n=341) were listed for transplantation after that date, most likely reflecting changing clinical practice over time associated with the publica-

Since a prospective randomised trial to assess the effect of ICD in end-stage heart failure is difficult to perform in a patient population that has been selected for heart transplantation, large scale observational studies provide the highest quality data available to address the clinically relevant question of whether these patients at particularly high risk will benefit from ICD implanta-

**CONCLUSION**

The present study suggests that both primary and secondary ICD implantation are associated with improved survival in patients with end-stage heart failure. Based on these results, patients listed for heart transplantation for whom in-hospital rhythm monitoring cannot be guaranteed until transplantation, might be considered for ICD implantation, irrespective of probable waiting time on the transplant list. While rates of ICD related complications, particularly inappropriate shocks and ICD related reoperation, were similar to those of previous randomised clinical trials, any decision to implant an ICD in a patient awaiting cardiac transplantation needs to be individualised and take into account the clinical equipoise of ICD therapy. Further, prospective randomised trials are now needed, before the findings of this study may be implemented in future guidelines.

**Contributors**

All authors contributed significantly to the manuscript and meet the criteria for authorship.

**Competing interests** Johannes Holmmeister is a guest speaker for St. Jude Medical, Boston Scientific and Biotronik and has received an honorarium from Biotronik. David Hüllemann is a guest speaker for St. Jude Medical and Medtronic and has received a consulting honorarium from St. Jude Medical and educational grants from Medtronic and Boston Scientific. Thomas F Lüscher has received research grants from Biotronik, Medtronic and St. Jude. Jan Stefl has received research grants and consulting honoraria from St. Jude Medical. Frank Ruschitzka is a guest speaker for St. Jude Medical and Biotronik.

**Ethics approval** Informed consent complying with the ICH Good Clinical Practice guidelines was obtained if required by the institutional review board or ethics committee, and the protocol was approved by the institutional review board or ethics committee in each country.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**

Heart failure


15 Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–442.


Abschnitt V
Lebenslauf
Mein Lebenslauf wird aus datenschutzrechtlichen Gründen in der elektronischen Version meiner Arbeit nicht veröffentlicht
Wissenschaftlicher Leistungsausweis

Deputy Editor für Open Heart – British Medical Journals, London, United Kingdom

Reviewer für: European Heart Journal (impact factor: 14.723)
Heart (impact factor: 6.023)
Transplant International (impact factor: 3.12)
Journal of Interventional Cardiology (impact factor: 1.318)
Abschnitt VI
Publikationsliste

Original articles

Impact factor: 7.440

Impact factor: 13.25

Impact factor: 7.28

**Impact factor: 1.318**


**Impact factor: 3.12**


**Impact factor: 6.023**


**Impact factor: 6.023**

**Impact factor:** 7.28


**Impact factor:** 14.723


**Impact factor:** 6.023


**Impact factor:** 14.948

endothelial function in patients with stable coronary artery disease: a double
-blind, randomized, placebo-controlled, cross-over study.


Impact factor: 14.723

Ruschitzka F, Enseleit F. Takotsubo cardiomyopathy has a unique cardiac
biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for
the differential diagnosis of acute coronary syndromes and stress induced

Impact factor: 6.175

14. Fröhlich G, Steffel J, Hürlimann D, Enseleit F, Lüscher TF, Ruschitzka F,
Abraham WT, Holzmeister J. Upgrading to resynchronization therapy after
chronic right ventricular pacing improves left ventricular remodelling. Eur Heart J.

Impact factor: 14.723

15. Seyfarth M, Sibbing D, Bauer I, Fröhlich G, Bott-Flügel L, Byrne R,
Dirschingenger J, Kastrati A, Schömig A. A randomized clinical trial to evaluate the
safety and efficacy of a percutaneous left ventricular assist device versus
intra-aortic balloon pumping for treatment of cardiogenic shock caused by

Impact factor: 15.343
**Impact factor: 1.302**

**Impact factor: 1.07**

**Impact factor: 0.72**
Articles currently under review


20. Georg M Fröhlich, Paul D Baxter, Christopher J Malkin, Julian A Scott, Neil E Moat, David Hildick-Smith, David Cunningham, Philip A MacCarthy, Uday Trivedi, Mark A de Belder, Peter F Ludman, Daniel J Blackman on behalf of the National Institute for Cardiovascular Outcomes Research (NICOR) Access route and survival in Transcatheter Aortic Valve Implantation (TAVI) Data from the UK TAVI Registry

21. Heerajnarain Bulluck, Steven K White MD, Georg Frohlich, Steven G Casson, Celia O’Meara, Ayla Newton, Jennifer Nicholas, Simon Wan, Alex Sirker, James C Moon, Derek M Yellon, Ashley Groves, Leon Menezes, Derek J Hausenloy Hybrid PET/MR metabolic imaging in the reperfused heart.
Reviews


Impact factor: 14.723


Impact factor: 7.745


Left main PCI: guidelines and technical considerations.

Cardiology International Autumn 2013.
Case reports


Impact factor: 5.808


Impact factor: 14.948

Editorials


Impact factor: 2.044


Impact factor: 6.023

Letters to the Editor


Heart. 2013 Oct;99(20):1543

Impact factor: 6.023

Impact factor: 6.023


Impact factor: 2.044


Most recent oral presentations

PCR London Valves meeting 2014 (28th-30th September)

- Late mechanical left main obstruction following TAVI: what next?

  "Best clinical case presentation" Award

- Plan B for a valve-in-valve TAVI procedure - Antegrade approach to cross an aortic bio-prosthesis
Abschnitt VII
Danksagung

Meinen Eltern